Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04717466 · ClinicalTrials.gov registry record · Phase 4
Brain Changes in Psoriasis After Secukinumab Treatment
A Phase 4 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT04717466 is a Phase 4 study that has completed, run by University of Miami. The registered enrollment target is 20 participants.
The verdict
NCT04717466, a Phase 4 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of a biologic drug targeting the Interleukin (IL)-17 pathway (secukinumab) on brain plasticity and examine whether the plastic changes correlate with the improvement of perception of well-being, itch, and pain in participants with psoriasis.
Interventions
- BIOLOGICAL Secukinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-06-29 |
| Est. Completion | 2025-03-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04717466
The ClinicalTrials.gov registry entry for NCT04717466 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Secukinumab is the first listed.
NCT04717466 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04717466 about?
NCT04717466 is a clinical study titled "Brain Changes in Psoriasis After Secukinumab Treatment". The purpose of this study is to assess the effect of a biologic drug targeting the Interleukin (IL)-17 pathway (secukinumab) on brain plasticity and examine whether the plastic changes correlate with the improvement of perception of well-being, itch, and pain in participants with psoriasis.
What is the current status of trial NCT04717466?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2021-06-29. Estimated completion is 2025-03-04.
What interventions are being tested in trial NCT04717466?
The interventions under investigation include: Secukinumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04717466?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.